Post-natalizumab disease reactivation in multiple sclerosis: systematic review and meta-analysis

BACKGROUND: Natalizumab (NTZ) is sometimes discontinued in patients with multiple sclerosis, mainly due to concerns about the risk of progressive multifocal leukoencephalopathy. However, NTZ interruption may result in recrudescence of disease activity. OBJECTIVE: The objective of this study was to s...

Descripción completa

Detalles Bibliográficos
Autores principales: Prosperini, Luca, Kinkel, Revere P., Miravalle, Augusto A., Iaffaldano, Pietro, Fantaccini, Simone
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Meta-Analysis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6444403/
https://www.ncbi.nlm.nih.gov/pubmed/30956686
http://dx.doi.org/10.1177/1756286419837809

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6444403/
https://www.ncbi.nlm.nih.gov/pubmed/30956686
http://dx.doi.org/10.1177/1756286419837809

Ejemplares similares